Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.40 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 10/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29348770 | 1.00 | JAK2 (0.44) | JAK2CD274PDCD1PDCD1LG2ALOX5AP | |
| SCHEMBL29348376 | 0.85 | JAK2 (0.39) | JAK2CD274PDCD1ALOX5APGRM2 | |
| SCHEMBL29348725 | 0.85 | JAK2 (0.41) | JAK2CD274PDCD1ALOX5AP | |
| SCHEMBL29348437 | 0.83 | CRBN (0.46) | JAK2CD274PDCD1PDCD1LG2 | |
| SCHEMBL31068149 | 0.83 | CRBN (0.46) | JAK2CD274PDCD1PDCD1LG2 | |
| SCHEMBL31068109 | 0.83 | CRBN (0.46) | JAK2CD274PDCD1PDCD1LG2 | |
| SCHEMBL29348439 | 0.83 | CRBN (0.46) | JAK2CD274PDCD1PDCD1LG2 | |
| SCHEMBL29348386 | 0.83 | CRBN (0.46) | JAK2CD274PDCD1PDCD1LG2 | |
| SCHEMBL31068294 | 0.76 | DDB1 (0.43) | JAK2CD274PDCD1ALOX5APGRM2 | |
| SCHEMBL29348475 | 0.76 | DDB1 (0.43) | JAK2CD274PDCD1ALOX5APGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |